http://www.nytimes.com/2015/09/21/bu...ests.html?_r=0
I'm of two minds on the subject.
On the one hand, the guy sounds like a real piece of ****. He is shamelessly price gouging an extremely vulnerable population, and his actions could very possibly result in unneeded deaths.
On the other hand, this isn't all THAT different from what established drug companies already routinely do. The argument that pharmaceutical companies routinely make is they invest billions of dollars in R&D, and they need to charge a borderline outrageous price to fund their R&D and generate an attractive ROI for investors. Suppose that this guy is legitimately going to invest the proceeds from this into R&D on new drugs. If that is the case, then one could simply argue that all he has done is reverse the order of what established companies are already doing, and ethically he hasn't really done anything wrong at all.
Thoughts?